Therapeutic Response Statement (Sensitivity) Deprecated

This therapeutic response statement Supports the relationship that v::ALK status confers therapeutic sensitivity to Lorlatinib in patients with Non-Small Cell Lung Cancer.

The Republic of Ireland's Health Service Executive (HSE) has approved loralatinib for reimbursement as a monotherapy treatment option for adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

This statement is based on a regulatory approval from the Health Service Executive:

As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously not treated with an ALK inhibitor.

Citation

Lorlatinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6889/570_V3_Lorlatinib_therapy_.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2020-10-01	Health Service Executive	Indication approved for reimbursement.